Moneycontrol
    Moneycontrol PRO
    LAMF
    LAMF

    Jump to

    • Will make $10-20 mn annually on Brazil drug nod: Nectar

    • Expect double-digit growth in FY15: Nectar Life

    • See 2% margin growth in FY14: Nectar Lifesciences

      In an upbeat mood post the numbers, Aryan Goyal of Nectar Lifesciences is confident that the company would see robust numbers going ahead.

    • API facility to boost revenue by 5-10%: Nectar Lifesciences

      Nectar Lifesciences has received European approval for its Cephalosporin APIs manufacturing facility at Derabassi in Punjab. Dinesh Dua, chief executive director at Nectar Lifesciences, in an interview to CNBC-TV18, said the API manufacturing facility is likely to boost the company’s revenues by 5-10%.

    • USFDA nod will open up lucrative market for us: Nectar Lifesciences

      In an interview with CNBC-TV18, Dinesh Dua, CEO of Nectar Lifesciences said, "It’s going to happen at April. As soon as the approval is through we will be able to supply our API to lots of customers."

    • Nectar Lifesciences targets Rs 1300cr revenues in FY12

      In an interview with CNBC-TV18, Dinesh Dua, CEO of Nectar Lifesciences said,"We are looking at about close to Rs 1,300 plus crore topline for the next year."

    Advisory Alert:

    It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347